sacubitril/valsartan (Entresto) -

sacubitril/valsartan (Entresto)
Information type: Guidance
Source: Scottish Medicines Consortium
Specialities: Cardiovascular system disorders
Summary
The SMC has accepted sacubitril/valsartan for use in NHS Scotland for use in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.
UKMi comment
Separately, DRAFT NICE Guidance recommends sacubitril valsartan as an option for treating people with heart failure with reduced ejection fraction, only in people:

• with New York Heart Association (NYHA) class II to III chronic heart failure and

• who are already taking a stable dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor-blockers (ARBs) and

• with a left ventricular ejection fraction of 35% or less.
Related links: DRAFT NICE TA